PRNewswire

SUZHOU, China, Nov. 13, 2024 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that a clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: